The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma–Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses

Russell Maxwell, Andrew S. Luksik, Tomas Garzon-Muvdi, Michael Lim

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Purpose of Review: Malignant gliomas, including glioblastoma and anaplastic astrocytoma, are the most frequent primary brain tumors and present with many treatment challenges. In this review, we discuss the potential of cellular- and viral-based immunotherapies in the treatment of malignant glioma, specifically focusing on dendritic cell vaccines, adoptive cell therapy, and oncolytic viruses. Recent Findings: Diverse cellular- and viral-based strategies have been engineered and optimized to generate either a specific or broad antitumor immune response in malignant glioma. Due to their successes in the preclinical arena, many of these therapies have undergone phase I and II clinical testing. These early clinical trials have demonstrated the feasibility, safety, and efficacy of these immunotherapies. Summary: Dendritic cell vaccines, adoptive cell transfer, and oncolytic viruses may have a potential role in the treatment of malignant glioma. However, these modalities must be investigated in well-designed phase III trials to prove their efficacy.

Original languageEnglish (US)
Article number50
JournalCurrent Neurology and Neuroscience Reports
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Keywords

  • Adoptive cell transfer
  • CAR T cells
  • Dendritic cell vaccines
  • Glioma
  • Immunotherapy
  • Oncolytic virus

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma–Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses'. Together they form a unique fingerprint.

  • Cite this